Drugs / MVA-BN-RSV
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02864628 | Sep 2016 → Oct 2017 | respiratory syncytial virus infectious disease | Bavarian Nordic | Withdrawn | No outcome recorded |
| Phase 1 | NCT02419391 | Aug → Dec 2015 | respiratory syncytial virus infectious disease | Bavarian Nordic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02873286 | Sep 2016 → Dec 2018 | respiratory syncytial virus infectious disease | Bavarian Nordic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05238025 | Apr 2022 → Jun 2023 | respiratory syncytial virus infectious disease | Bavarian Nordic | Terminated | Mixed |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-08-08 | Bavarian Nordic | Results Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine bavarian-nordic.com ↗
Broad antibody and T cell responses against RSV remained durable 1 year post a single vaccination with MVA-BN ® RSV in the majority of subjects |
| 2016-05-23 | Bavarian Nordic | Results Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations bavarian-nordic.com ↗
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced positive top line results from its first-in-man Phase 1 trial of its novel, broad spectrum vaccine for respiratory syncytial virus (RSV). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-08-08 | Bavarian Nordic | Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine bavarian-nordic.com ↗ |
| 2016-05-23 | Bavarian Nordic | Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations bavarian-nordic.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-RSV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864628 ↗ |
| Modality | Vaccine | “Recombinant MVA BN® RSV Vaccine” NCT02419391 ↗ |
| Route | Intranasal | “intranasal application” NCT02864628 ↗ |